Form 8-K HALOZYME THERAPEUTICS, For: Jan 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Halozyme provides preliminary 2025 revenue estimates
January 28, 2026 6:41 AM ESTHalozyme Therapeutics Inc. (NASDAQ: HALO) provided preliminary financial estimates for 2025 during a January 28 investor conference call and press release.
The company estimated 2025 revenue in the range of $1.385 billion to $1.4 billion. Royalties are projected between $865 million and $870 million, while product sales are estimated at $372 million to... More
